Analysts anticipate Q3 revenue of $73.53 billion and EPS of $7.46, as Cigna's current stock price of $295.19 trades significantly below the $342.29 average analyst price target.
Investors are primarily focusing on the Medical Care Ratio (MCR), which is estimated to reach 85.13%, to assess the impact of rising medical utilization on insurance segment profitability.
Expectations reflect a projected year-over-year EPS decline of 4.7% due to higher medical cost trends, partially offset by robust growth in the Evernorth pharmacy services division. Analysts are also monitoring the success of biosimilar integration and performance in the specialty pharmacy segment as critical long-term growth drivers.